Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells
Wang et al., 2024, Cancer Cell 42, 1–16 In the new era of cancer treatment, immunotherapy has become a revolutionary therapeutic approach. Particularly, immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 antibodies have significantly improved the survival rates of patients with various types of cancer. Immune checkpoint inhibitors enhance the body’s immune response to cancer […]
Single cell view of tumor microenvironment gradients in pleural mesothelioma
Giotti, B., Dolasia, K., Zhao, W., Cai, P., Sweeney, R., Merritt, E., Kiner, E., Kim, G. S., Bhagwat, A., Nguyen, T., Hegde, S., Fitzgerald, B. G., Shroff, S., Dawson, T., Garcia-Barros, M., Abdul-Ghafar, J., Chen, R., Gnjatic, S., Soto, A., . . . Tsankov, A. M. (2024). Cancer Discovery, 14(11), 2262–2278. https://doi.org/10.1158/2159-8290.cd-23-0017 Immunotherapies have shown […]
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Guan, X., Hu, R., Choi, Y., Srivats, S., Nabet, B. Y., Silva, J., McGinnis, L., Hendricks, R., Nutsch, K., Banta, K. L., Duong, E., Dunkle, A., Chang, P. S., Han, C., Mittman, S., Molden, N., Daggumati, P., Connolly, W., Johnson, M., . . . Patil, N. S. (2024). Anti-TIGIT antibody improves PD-L1 blockade through myeloid […]
Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T cell function
Jain, N., Zhao, Z., Koche, R. P., Antelope, C., Gozlan, Y., Montalbano, A., Brocks, D., Lopez, M., Dobrin, A., Shi, Y., Gunset, G., Giavridis, T., & Sadelain, M. (2023). Cancer Discovery, 14(1), 142–157. https://doi.org/10.1158/2159-8290.cd-22-1319 Suboptimal functional persistence limits the efficacy of adoptive T cell therapies. CD28-based chimeric antigen receptors (CARs) impart potent effector function to […]
Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy
Guo, Y., Bao, Q., Hu, P., & Shi, J. (2023). Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-42972-2 Pro-tumoral macrophages in lung tumors present a significant challenge in immunotherapy. Here, we introduce a pH-responsive nanomedicine approach for activating anti-tumoral macrophages and dendritic cells. Using a layered double hydroxide nanosheet carrier, we co-deliver a T-type calcium channel inhibitor (TTA-Q6) and […]